Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 614
Filter
2.
Asian Pac J Cancer Prev ; 25(5): 1589-1598, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38809630

ABSTRACT

INTRODUCTION: Diagnosis of the majority of hepatocellular carcinoma (HCC) patients occurs at intermediate to advanced stages, with a few curative therapeutic options being available. It is therefore strongly urgent to discover additional adjuvant therapy for this lethal malignancy. This study aimed to assess the effectiveness of curcumin (C), piperine (P) and taurine (T) combination as adjuvant agents on serum levels of IFN-γ, immunophenotypic and molecular characterization of mononuclear leukocytes (MNLs) in HCC patients treated with Transarterial chemoembolization (TACE). PATIENTS AND METHODS: Serum and MNLs were collected from 20 TACE-treated HCC patients before (baseline-control samples) and after treatment with 5 g curcumin capsules , 10 mg piperine and 0.5 mg taurine taken daily for three consecutive months. Immunophenotypic and molecular characterization of MNLs were determined by flow cytometry and quantitative real time PCR, respectively. In addition, serum IFN-γ level was quantified by ELISA. RESULTS: After receiving treatment with CPT combination, there was a highly significant increase in IFN- γ levels in the sera of patients when compared to basal line control samples. Additionally, the group receiving combined therapy demonstrated a downregulation in the expression levels of PD-1, in MNLs as compared to controls. MNLs' immunophenotyping revealed a significant decline in CD4+CD25+cells (regulatory T lymphocytes). Furthermore, clinicopathological characteristics revealed a highly significant impact of CPT combination on aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and alpha feto protein (AFP) levels. CONCLUSION: This study introduces a promising adjuvant CPT combined treatment as natural agents to enhance the management of HCC patients who are candidates to TACE treatment.


Subject(s)
Alkaloids , Antineoplastic Combined Chemotherapy Protocols , Benzodioxoles , Carcinoma, Hepatocellular , Chemoembolization, Therapeutic , Curcumin , Liver Neoplasms , Piperidines , Polyunsaturated Alkamides , Taurine , Humans , Carcinoma, Hepatocellular/therapy , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/therapy , Liver Neoplasms/pathology , Liver Neoplasms/drug therapy , Alkaloids/administration & dosage , Alkaloids/therapeutic use , Piperidines/administration & dosage , Piperidines/therapeutic use , Chemoembolization, Therapeutic/methods , Pilot Projects , Male , Curcumin/therapeutic use , Curcumin/administration & dosage , Female , Polyunsaturated Alkamides/pharmacology , Polyunsaturated Alkamides/administration & dosage , Polyunsaturated Alkamides/therapeutic use , Benzodioxoles/therapeutic use , Benzodioxoles/administration & dosage , Middle Aged , Taurine/administration & dosage , Taurine/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Interferon-gamma/metabolism , Prognosis , Follow-Up Studies , Leukocytes, Mononuclear/metabolism , Adult , Aged
3.
BMC Pulm Med ; 24(1): 260, 2024 May 28.
Article in English | MEDLINE | ID: mdl-38807122

ABSTRACT

BACKGROUND: Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients. However, there are several other valuable CPET parameters describing exercise tolerance (Wpeak, VO2VT1, VO2VT2, VO2/HRpeak, etc.), and helping to better understand the effect of specific treatment (VE, VT, VD/VT etc.). Limited data showed ambiguous results of this improvement after CFTR modulator treatment. Elexacaftor/tezacaftor/ivacaftor medication improves pulmonary function and quality of life, whereas its effect on CPET has yet to be sufficiently demonstrated. METHODS: We performed a single group prospective observational study of 10 adolescent patients with cystic fibrosis who completed two CPET measurements between January 2019 and February 2023. During this period, elexacaftor/tezacaftor/ivacaftor treatment was initiated in all of them. The first CPET at the baseline was followed by controlled CPET at least one year after medication commencement. We focused on interpreting the data on their influence by the novel therapy. We hypothesized improvements in cardiorespiratory fitness following treatment. We applied the Wilcoxon signed-rank test. The data were adjusted for age at the time of CPET to eliminate bias of aging in adolescent patients. RESULTS: We observed significant improvement in peak workload, VO2 peak, VO2VT1, VO2VT2, VE/VCO2 slope, VE, VT, RQ, VO2/HR peak and RR peak. The mean change in VO2 peak was 5.7 mL/kg/min, or 15.9% of the reference value (SD ± 16.6; p= 0.014). VO2VT1 improved by 15% of the reference value (SD ± 0.1; p= 0.014), VO2VT2 improved by 0.5 (SD ± 0.4; p= 0.01). There were no differences in other parameters. CONCLUSION: Exercise tolerance improved after elexacaftor/tezacaftor/ivacaftor treatment initiation. We suggest that the CFTR modulator alone is not enough for recovering physical decondition, but should be supplemented with physical activity and respiratory physiotherapy. Further studies are needed to examine the effect of CFTR modulators and physical therapy on cardiopulmonary exercise tolerance.


Subject(s)
Aminophenols , Benzodioxoles , Cystic Fibrosis , Drug Combinations , Indoles , Pyrazoles , Pyridines , Quinolones , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Adolescent , Male , Female , Prospective Studies , Pilot Projects , Indoles/therapeutic use , Benzodioxoles/therapeutic use , Quinolones/therapeutic use , Aminophenols/therapeutic use , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Cardiorespiratory Fitness , Exercise Test , Pyrroles/therapeutic use , Exercise Tolerance/drug effects , Oxygen Consumption , Child , Pyrrolidines
4.
Ther Adv Respir Dis ; 18: 17534666241254090, 2024.
Article in English | MEDLINE | ID: mdl-38780228

ABSTRACT

BACKGROUND: A significant decline in pulmonary exacerbation rates has been reported in CF patients homozygous for F508del treated with lumacaftor/ivacaftor. However, it is still unclear whether this reduction reflects a diminished microbiological burden. OBJECTIVES: The aim of this study was to determine the impact of lumacaftor/ivacaftor on the bacterial and fungal burden. DESIGN: The study is a prospective multicenter cohort study including 132 CF patients homozygous for F508del treated with lumacaftor/ivacaftor. METHODS: Clinical parameters as well as bacterial and fungal outcomes 1 year after initiation of lumacaftor/ivacaftor were compared to data from 2 years prior to initiation of the treatment. Changes in the slope of the outcomes before and after the onset of treatment were assessed. RESULTS: Lung function measured as ppFEV1 (p < 0.001), body mass index (BMI) in adults (p < 0.001), and BMI z-score in children (p = 0.007) were improved after initiation of lumacaftor/ivacaftor. In addition, the slope of the prevalence of Streptococcus pneumoniae (p = 0.007) and Stenotrophomonas maltophilia (p < 0.001) shifted from positive to negative, that is, became less prevalent, 1 year after treatment, while the slope for Candida albicans (p = 0.009), Penicillium spp (p = 0.026), and Scedosporium apiospermum (p < 0.001) shifted from negative to positive. CONCLUSION: The current study showed a significant improvement in clinical parameters and a reduction of some of CF respiratory microorganisms 1 year after starting with lumacaftor/ivacaftor. However, no significant changes were observed for Pseudomonas aeruginosa, Staphylococcus aureus, or Aspergillus fumigatus, key pathogens in the CF context.


Subject(s)
Aminophenols , Aminopyridines , Benzodioxoles , Cystic Fibrosis , Drug Combinations , Quinolones , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/microbiology , Cystic Fibrosis/physiopathology , Male , Prospective Studies , Female , Aminophenols/therapeutic use , Benzodioxoles/therapeutic use , Child , Adult , Young Adult , Adolescent , Aminopyridines/pharmacology , Aminopyridines/administration & dosage , Aminopyridines/therapeutic use , Aminopyridines/adverse effects , Quinolones/pharmacology , Sweden , Treatment Outcome , Mycoses/microbiology , Mycoses/drug therapy , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/diagnosis , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Lung/microbiology , Lung/physiopathology , Lung/drug effects , Chloride Channel Agonists/therapeutic use , Time Factors , Fungi/isolation & purification , Bacterial Infections/microbiology , Bacterial Infections/drug therapy
5.
PLoS One ; 19(5): e0304555, 2024.
Article in English | MEDLINE | ID: mdl-38820269

ABSTRACT

Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1ß (p<0.0013, p = 0.0476), IL-6 (p = 0.0109, p = 0.0216) and TNF (p = 0.0028, p = 0.0033) levels in CF serum and following PBMCs stimulation respectively. The corresponding mRNA levels were also found to be reduced in stimulated PBMCs, as well as reduced ASC specks and caspase-1 levels, indicative of NLRP3-mediated production of pro-inflammatory cytokines, IL-1ß and IL-18. While ETI therapy is highly effective at reducing sweat chloride and improving lung function, it also displays potent anti-inflammatory properties, which are likely to contribute to improved long-term clinical outcomes.


Subject(s)
Aminophenols , Anti-Inflammatory Agents , Benzodioxoles , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Cytokines , Indoles , Quinolones , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/genetics , Benzodioxoles/therapeutic use , Benzodioxoles/pharmacology , Adult , Aminophenols/therapeutic use , Female , Indoles/therapeutic use , Indoles/pharmacology , Male , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Quinolones/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents/pharmacology , Cytokines/metabolism , Cytokines/blood , Pyrazoles/therapeutic use , Pyrazoles/pharmacology , Young Adult , Pyridines/therapeutic use , Pyridines/pharmacology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/drug effects , C-Reactive Protein/metabolism , Pyrroles/therapeutic use , Pyrroles/pharmacology , Sweat/chemistry , Sweat/metabolism , Pyrrolidines
6.
Respir Med ; 228: 107664, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38759874

ABSTRACT

BACKGROUND: Impaired glycemic control and the subsequent development of Cystic fibrosis Related Diabetes (CFRD) are prevalent complications, affecting up to 50 % of adults with cystic fibrosis (CF). CFTR modulator (CFTRm) therapies improve pulmonary functions, reduce exacerbation rates, increase survival in people with CF (pwCF) and appear to have a positive effect on extrapulmonary manifestations, such as nutritional state, improvements in upper respiratory symptoms, and quality of life. Initial findings indicate that CFTRm may have a positive impact on short-term glycemic control; however, long-term effects remain uncertain at present. METHODS: In this retrospective study, data were collected and analyzed on 15 pwCF, ages 13-37 years, started on CFTRm therapy. Oral Glucose Tolerance Test (OGTT) results were compared pre- and post-CFTRm therapy. RESULTS: The 120-min OGTT value decreased from 159.7 mg/dL to 130.4 mg/dL post-CFTRm (p = 0.047). The average time elapsed between the two OGTTs was 49.87 months (ranging 9-157 months, median 38 months). Glycemic status improved in six pwCF (two CFRD to normal (NGT)/indeterminate (INDET) glucose tolerance; two impaired glucose tolerance (IGT) to INDET; two INDET to NGT) and worsened in one (IGT to CFRD). Six pwCF and NGT remained stable with no changes in glycemic status throughout the follow-up period. CONCLUSIONS: CFTRm therapy may decelerate the glycemic control deterioration in pwCF over an extended period. These findings indicate the need for periodic OGTTs following the initiation of CFTRm therapy to appropriately adjust insulin requirements and prevent hypoglycemia. Further larger cohorts are required to authenticate and substantiate these findings.


Subject(s)
Blood Glucose , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Glucose Tolerance Test , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Cystic Fibrosis/complications , Adolescent , Adult , Retrospective Studies , Male , Female , Young Adult , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Blood Glucose/metabolism , Blood Glucose/drug effects , Aminophenols/therapeutic use , Quinolones/therapeutic use , Aminopyridines/therapeutic use , Benzodioxoles/therapeutic use , Diabetes Mellitus/drug therapy , Diabetes Mellitus/metabolism , Glycemic Control/methods , Time Factors , Glucose/metabolism , Glucose Intolerance/drug therapy , Glucose Intolerance/metabolism
7.
Int J Mol Sci ; 25(8)2024 Apr 22.
Article in English | MEDLINE | ID: mdl-38674150

ABSTRACT

Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer's disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer's disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.


Subject(s)
Benzodioxoles , Drug Repositioning , Quinazolines , Humans , Drug Repositioning/methods , Quinazolines/therapeutic use , Quinazolines/chemistry , Quinazolines/pharmacology , Benzodioxoles/therapeutic use , Benzodioxoles/chemistry , Benzodioxoles/pharmacology , Animals , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/adverse effects , Alzheimer Disease/drug therapy , src-Family Kinases/antagonists & inhibitors , src-Family Kinases/metabolism , Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/chemistry
8.
Sci Rep ; 14(1): 9465, 2024 04 24.
Article in English | MEDLINE | ID: mdl-38658613

ABSTRACT

A poor nutritional status is associated with worse pulmonary function and survival in people with cystic fibrosis (pwCF). CF transmembrane conductance regulator modulators can improve pulmonary function and body weight, but more data is needed to evaluate its effects on body composition. In this retrospective study, a pre-trained deep-learning network was used to perform a fully automated body composition analysis on chest CTs from 66 adult pwCF before and after receiving elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Muscle and adipose tissues were quantified and divided by bone volume to obtain body size-adjusted ratios. After receiving ETI therapy, marked increases were observed in all adipose tissue ratios among pwCF, including the total adipose tissue ratio (+ 46.21%, p < 0.001). In contrast, only small, but statistically significant increases of the muscle ratio were measured in the overall study population (+ 1.63%, p = 0.008). Study participants who were initially categorized as underweight experienced more pronounced effects on total adipose tissue ratio (p = 0.002), while gains in muscle ratio were equally distributed across BMI categories (p = 0.832). Our findings suggest that ETI therapy primarily affects adipose tissues, not muscle tissue, in adults with CF. These effects are primarily observed among pwCF who were initially underweight. Our findings may have implications for the future nutritional management of pwCF.


Subject(s)
Aminophenols , Benzodioxoles , Body Composition , Cystic Fibrosis , Drug Combinations , Indoles , Quinolines , Quinolones , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Male , Adult , Female , Body Composition/drug effects , Aminophenols/therapeutic use , Quinolones/therapeutic use , Benzodioxoles/therapeutic use , Retrospective Studies , Indoles/therapeutic use , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Tomography, X-Ray Computed , Young Adult , Pyrrolidines/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Adipose Tissue/diagnostic imaging , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Nutritional Status
9.
Pediatr Pulmonol ; 59(6): 1622-1630, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38558542

ABSTRACT

BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has revolutionized cystic fibrosis (CF) treatment. However, previous research has demonstrated profound global disparities in diagnosis and treatment access. If unaddressed, these threaten to widen existing health inequities. Therefore, in this analysis we aimed to reappraise gaps and evaluate progress in diagnosis and treatment equity in high-income (HIC) versus low- and middle-income countries (LMICs). METHODS: Estimates of the global CF population were made in 158 countries using patient registries, systematic literature searches, and an international survey of 14 CF experts. Estimates of the global burden of undiagnosed CF were made using epidemiological studies identified in literature searches and registry coverage data. The proportion of people receiving ETI was estimated using publicly available revenue data and a survey of 23 national drug pricing databases. RESULTS: 188,336 (163,421-209,204) people are estimated to have CF in 96 countries. Of these, 111,767 (59%) were diagnosed and 51,322 (27%) received ETI. The undiagnosed patient burden is estimated to be 76,569 people, with 82% in LMICs. ETI is reimbursed in 35 HICs, but only one LMIC. Four years after approval, there are 13,723 people diagnosed with CF who live in a country where ETI is inaccessible. This increases to 76,199 when including the estimated undiagnosed population. CONCLUSIONS: Equitable access to CFTR modulators must become a top priority for the international CF community. ETI costs up to $322,000 per year but could be manufactured for $5000 to allow access under a voluntary license. Given the extent of disparities, other mechanisms to improve access that circumvent the manufacturer should also be considered.


Subject(s)
Aminophenols , Cystic Fibrosis , Global Health , Health Services Accessibility , Healthcare Disparities , Quinolones , Cystic Fibrosis/diagnosis , Cystic Fibrosis/therapy , Cystic Fibrosis/drug therapy , Cystic Fibrosis/economics , Cystic Fibrosis/epidemiology , Humans , Health Services Accessibility/statistics & numerical data , Quinolones/therapeutic use , Aminophenols/therapeutic use , Aminophenols/economics , Healthcare Disparities/statistics & numerical data , Healthcare Disparities/economics , Benzodioxoles/therapeutic use , Drug Combinations , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Child , Developing Countries , Developed Countries/statistics & numerical data , Indoles , Quinolines
10.
Pediatr Pulmonol ; 59(6): 1724-1730, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38607242

ABSTRACT

BACKGROUND: Cystic fibrosis (CF) is caused by CF transmembrane conductance regulator (CFTR) gene mutations producing dysfunctional CFTR proteins leading to progressive clinical disease. Elexacaftor-tezacaftor-ivacaftor (ETI) remarkably improves lung disease but is associated with substantial weight gain. STUDY DESIGN AND METHODS: We performed a single-center longitudinal study predicting 6-month weight gain after ETI initiation. We used linear mixed effects modeling (LME) to determine association of ETI treatment with changing body mass index (BMI). Using linear regression, we examined BMI prediction models with distinct combinations of main effects to identify a model useful for patient counseling. We used up to eight commonly observed clinical characteristics as input variables (age, sex, percent predicted FEV1 [FEV1%], F508del homozygous state, pancreatic sufficiency, HgbA1c, prior modulator use and prior year number of pulmonary exacerbations). RESULTS: We evaluated 154 patients (19-73 years old, 54% female, FEV1% = 19-121, 0-6 prior year pulmonary exacerbations). LME demonstrated an association between ETI use and weight increases. Exhaustive testing suggested a parsimonious linear regression model well-fitted to data that is potentially useful for counseling. The two variable model shows that on average, BMI decreases by 0.045 (95% Confidence Interval [CI] = -0.069 to -0.021, p < 0.001) for every year of age and increases by 0.322 (CI = 0.142 to 0.502, p = 0.001) for each additional prior year exacerbation at the time of ETI initiation. INTERPRETATION: Young patients with many prior year pulmonary exacerbations likely have the largest 6 month weight gain after starting ETI.


Subject(s)
Aminophenols , Body Mass Index , Cystic Fibrosis , Drug Combinations , Indoles , Weight Gain , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Cystic Fibrosis/genetics , Female , Male , Weight Gain/drug effects , Adult , Aminophenols/therapeutic use , Young Adult , Middle Aged , Longitudinal Studies , Indoles/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Quinolones/therapeutic use , Aged , Benzodioxoles/therapeutic use , Pyrroles/therapeutic use , Pyridines/therapeutic use , Pyrazoles/therapeutic use , Quinolines
11.
mBio ; 15(5): e0051924, 2024 May 08.
Article in English | MEDLINE | ID: mdl-38564694

ABSTRACT

Today, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given the drastic respiratory symptom improvement experienced by many post-ETI, clinical studies are already underway to reduce the number of respiratory therapies, including antibiotic regimens, that pwCF historically relied on to combat lung disease progression. Early studies suggest that bacterial burden in the lungs is reduced post-ETI, yet it is unknown how chronic Pseudomonas aeruginosa populations are impacted by ETI. We found that pwCF remain infected throughout their upper and lower respiratory tract with their same strain of P. aeruginosa post-ETI, and these strains continue to evolve in response to the newly CFTR-corrected airway. Our work underscores the continued importance of CF airway microbiology in the new era of highly effective CFTR modulator therapy. IMPORTANCE: The highly effective cystic fibrosis transmembrane conductance regulator modulator therapy Elexakaftor/Tezacaftor/Ivacaftor (ETI) has changed cystic fibrosis (CF) disease for many people with cystic fibrosis. While respiratory symptoms are improved by ETI, we found that people with CF remain infected with Pseudomonas aeruginosa. How these persistent and evolving bacterial populations will impact the clinical manifestations of CF in the coming years remains to be seen, but the role and potentially changing face of infection in CF should not be discounted in the era of highly effective modulator therapy.


Subject(s)
Aminophenols , Benzodioxoles , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Drug Combinations , Indoles , Pseudomonas Infections , Pseudomonas aeruginosa , Quinolones , Cystic Fibrosis/microbiology , Cystic Fibrosis/drug therapy , Cystic Fibrosis/complications , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics , Humans , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Aminophenols/therapeutic use , Quinolones/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Benzodioxoles/therapeutic use , Indoles/therapeutic use , Pyrazoles/therapeutic use , Pyrroles/therapeutic use , Pyridines/therapeutic use , Thiophenes/therapeutic use , Thiophenes/pharmacology , Female , Quinolines
12.
JCI Insight ; 9(8)2024 Apr 22.
Article in English | MEDLINE | ID: mdl-38646935

ABSTRACT

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with F508del being the most prevalent mutation. The combination of CFTR modulators (potentiator and correctors) has provided benefit to CF patients carrying the F508del mutation; however, the safety and effectiveness of in utero combination modulator therapy remains unclear. We created a F508del ferret model to test whether ivacaftor/lumacaftor (VX-770/VX-809) therapy can rescue in utero and postnatal pathologies associated with CF. Using primary intestinal organoids and air-liquid interface cultures of airway epithelia, we demonstrate that the F508del mutation in ferret CFTR results in a severe folding and trafficking defect, which can be partially restored by treatment with CFTR modulators. In utero treatment of pregnant jills with ivacaftor/lumacaftor prevented meconium ileus at birth in F508del kits and sustained postnatal treatment of CF offspring improved survival and partially protected from pancreatic insufficiency. Withdrawal of ivacaftor/lumacaftor treatment from juvenile CF ferrets reestablished pancreatic and lung diseases, with altered pulmonary mechanics. These findings suggest that in utero intervention with a combination of CFTR modulators may provide therapeutic benefits to individuals with F508del. This CFTR-F508del ferret model may be useful for testing therapies using clinically translatable endpoints.


Subject(s)
Aminophenols , Aminopyridines , Benzodioxoles , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Ferrets , Quinolones , Animals , Female , Pregnancy , Aminophenols/therapeutic use , Aminophenols/pharmacology , Aminopyridines/pharmacology , Aminopyridines/therapeutic use , Benzodioxoles/therapeutic use , Benzodioxoles/pharmacology , Chloride Channel Agonists/therapeutic use , Chloride Channel Agonists/pharmacology , Cystic Fibrosis/genetics , Cystic Fibrosis/drug therapy , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Disease Models, Animal , Drug Combinations , Mutation , Quinolones/pharmacology , Quinolones/therapeutic use
13.
Nutrition ; 123: 112425, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38621324

ABSTRACT

OBJECTIVE: Treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators in individuals with cystic fibrosis (CF) has brought a significant change in forced expiratory volume in 1 second (FEV1) and clinical parameters. However, it also results in weight gain. The aim of our study is to evaluate the effect of CFTR modulator treatment on body composition, measured by computed tomography (CT). METHODS: Adult subjects with CF under follow-up at La Princesa University Hospital were recruited. All of them were on elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) treatment. Body composition analysis was conducted using CT scans and an open-source software. The results were then compared with bioimpedance estimations, as well as other clinical and spirometry data. RESULTS: Our sample consisted of 26 adult subjects. The fat mass compartments on CT scans correlated with similar compartments on bioimpedance, and normal-density muscle mass exhibited a strong correlation with phase angle. Higher levels of very low-density muscle prior to treatment were associated with lower final FEV1 and less improvement in FEV1 after therapy. We observed an increase in total body area (P < 0.001), driven by increases in total fat mass (P < 0.001), subcutaneous fat (P < 0.001), visceral fat (P = 0.002), and intermuscular fat (P = 0.022). The only muscle compartment that showed an increase after treatment was very low-density muscle (P = 0.032). CONCLUSIONS: CT scans represent an opportunity to assess body composition on CF. Combination treatment with CFTR modulators, leads to an improvement in FEV1 and to an increase in body mass in all compartments primarily at the expense of fat mass.


Subject(s)
Aminophenols , Body Composition , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Drug Combinations , Quinolones , Tomography, X-Ray Computed , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/physiopathology , Cystic Fibrosis/diagnostic imaging , Adult , Body Composition/drug effects , Male , Female , Tomography, X-Ray Computed/methods , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/drug effects , Aminophenols/therapeutic use , Quinolones/therapeutic use , Quinolones/pharmacology , Follow-Up Studies , Young Adult , Indoles/pharmacology , Indoles/therapeutic use , Forced Expiratory Volume/drug effects , Benzodioxoles/therapeutic use , Benzodioxoles/pharmacology , Electric Impedance
14.
Ther Adv Respir Dis ; 18: 17534666241235054, 2024.
Article in English | MEDLINE | ID: mdl-38554035

ABSTRACT

BACKGROUND: To limit the progression of disease, people with cystic fibrosis (pwCF) perform daily respiratory physiotherapy, which is perceived as the most burdensome routine in managing their condition. The elexacaftor-tezacaftor-ivacaftor (ETI) combination has changed respiratory management. OBJECTIVE: To investigate how the perceived treatment burden changed in 1 year of treatment with ETI. DESIGN: Prospective observational study. METHODS: Ad hoc questionnaires for the pwCF and for the caregivers of pwCF < 18 years were administered before the initiation of ETI therapy and then at 6-12 months. The Cystic Fibrosis Questionnaire-Revised (CFQ-R) and the Sinonasal Outcome Test (SNOT-22) were administered to explore disease-related symptoms and social limitations. The International Physical Activity Questionnaire was used to determine levels of physical activity. Mixed-effect models were fitted to explore whether the time engaged in respiratory physiotherapy changed during 1 year. RESULTS: The study included 47/184 pwCF aged 21.4 (5.7) years, who completed 1 year of ETI therapy. At 6 months, time on aerosol therapy was decreased by 2.5 (95% CI -32.9 to 27.8) min/day, time on airway clearance therapies (ACTs) was decreased by 8.8 (95% CI -25.9 to 8.3) min/day, and time for cleaning and disinfecting respiratory equipment was decreased by 10.6 (95% CI -26.5 to 5.3) min/day. At 1 year, gains in time saved were nearly 15 min/day on average. At 1 year, 5/47 (10.6%) pwCF reported that they had discontinued positive expiratory pressure mask. CONCLUSION: PwCF on ETI may note less time engaged in their daily respiratory physiotherapy routine. Nonetheless, aerosol therapy, ACTs and maintaining respiratory equipment were still perceived as time-consuming daily activities.


Understanding the challenges of respiratory physiotherapy in individuals with cystic fibrosis using triple therapy: a one-year study.In order to slow down the progression of their disease, people with cystic fibrosis typically do daily respiratory physiotherapy, which they find to be the most challenging part of managing their condition. The elexacaftor-tezacaftor-ivacaftor combination has changed how they manage their respiratory health. We wanted to see how the perceived difficulty of the treatment changed over one year of using elexacaftor-tezacaftor-ivacaftor. We gave questionnaires to people with cystic fibrosis and to their caregivers before they started the triple therapy and again at 6-12 months. We also used two international questionnaires to learn about symptoms and social limitations related to the disease. The International Physical Activity Questionnaire helped us understand their physical activity levels. We used statistical models to see if the time spent on respiratory physiotherapy changed over the year. Our study involved 47 individuals with cystic fibrosis, with an average age of 21 years, who completed one year of elexacaftor-tezacaftor-ivacaftor therapy. After 6 months, time spent on aerosol therapy decreased by 2.5 minutes per day, time on airway clearance therapies decreased by 8.8 minutes per day, and time for cleaning respiratory equipment decreased by 10.6 minutes per day. By the end of the year, they were saving almost 15 minutes per day on average. At one year, 5 out of 47 said they had stopped using the positive expiratory pressure mask. People with cystic fibrosis using elexacaftor-tezacaftor-ivacaftor may find that they spend less time on their daily respiratory physiotherapy routine. However, activities like aerosol therapy, airway clearance therapies, and maintaining respiratory equipment were still seen as time-consuming.


Subject(s)
Cystic Fibrosis , Indoles , Pyrazoles , Pyridines , Pyrrolidines , Quinolones , Humans , Aminophenols , Benzodioxoles/therapeutic use , Cystic Fibrosis/drug therapy , Physical Therapy Modalities , Respiratory Aerosols and Droplets
15.
Transpl Immunol ; 84: 102033, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38484898

ABSTRACT

Piperine, the major active substance in black pepper, has been shown to have anti-inflammatory and antioxidant effects in several ischemic diseases. However, the role of piperine in hepatic ischemia/reperfusion injury (HIRI) and its underlying mechanisms remain unclear. In this study, the mice were administered piperine (30 mg/kg) intragastric administration before surgery. After 24 h of hepatic ischemia-reperfusion, liver histopathological evaluation, serum transaminase measurements, and TUNEL analysis were performed. The infiltration of inflammatory cells and production of inflammatory mediators in the liver tissue were determined by immunofluorescence and immunohistochemical staining. The protein levels of toll-like receptor 4 (TLR4) and related proteins such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), interleukin-1 receptor-associated kinase 1 (IRAK1), p65, and p38 were detected by western blotting. The results showed that plasma aminotransferase (ALT), aspartate aminotransferase (AST), hepatocyte apoptosis, oxidative stress, and inflammatory cell infiltration significantly increased in HIRI mice. Piperine pretreatment notably repaired liver function, improved the histopathology and apoptosis of liver cells, alleviated oxidative stress injury, and reduced inflammatory cell infiltration. Further analysis showed that piperine attenuated tumor necrosis factor-a (TNF-α) and interleukin 6 (IL-6) production and reduced TLR4 activation and phosphorylation of IRAK1, p38, and NF-κB in HIRI. Piperine has a protective effect against HIRI through the TLR4/IRAK1/NF-κB signaling pathway and may be a safer option for future clinical treatment and prevention of ischemia-related diseases.


Subject(s)
Alkaloids , Benzodioxoles , Liver , Piperidines , Polyunsaturated Alkamides , Reperfusion Injury , Signal Transduction , Toll-Like Receptor 4 , Animals , Polyunsaturated Alkamides/therapeutic use , Polyunsaturated Alkamides/pharmacology , Benzodioxoles/pharmacology , Benzodioxoles/therapeutic use , Piperidines/pharmacology , Piperidines/therapeutic use , Alkaloids/pharmacology , Alkaloids/therapeutic use , Toll-Like Receptor 4/metabolism , Mice , Reperfusion Injury/drug therapy , Reperfusion Injury/metabolism , Signal Transduction/drug effects , Liver/pathology , Liver/drug effects , Liver/metabolism , Male , Apoptosis/drug effects , NF-kappa B/metabolism , Oxidative Stress/drug effects , Interleukin-1 Receptor-Associated Kinases/metabolism , Liver Diseases/drug therapy , Liver Diseases/metabolism , Liver Diseases/pathology , Humans , Mice, Inbred C57BL , Disease Models, Animal
16.
J Cyst Fibros ; 23(2): 203-207, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38431442

ABSTRACT

This review synthesizes articles published in 2023, focusing on the impact of elexacaftor-tezacaftor-ivacaftor (ETI) in cystic fibrosis (CF) care. Real-world data highlights sustained benefits of ETI across age groups, while challenges like neuropsychological side effects persist. Beyond CFTR modulators, research explores telemedicine and novel therapies. Prioritizing equitable access and addressing unmet needs remain crucial for comprehensive CF management.


Subject(s)
Aminophenols , Cystic Fibrosis , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/therapy , Aminophenols/therapeutic use , Quinolones/therapeutic use , Drug Combinations , Benzodioxoles/therapeutic use , Indoles/therapeutic use , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Chloride Channel Agonists/therapeutic use , Pyrrolidines/therapeutic use , Telemedicine/trends
18.
Pediatr Pulmonol ; 59(6): 1614-1621, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38456611

ABSTRACT

INTRODUCTION: Cystic fibrosis (CF) treatment has increasingly focused on highly effective modulators. Despite measurable benefits of modulators, there is little guidance for CF care team members on providing education and support to patients regarding initiation of these therapies. We aimed to explore patient, caregiver, and clinician perceptions of modulators and influences on decisions about starting cystic fibrosis transmembrane regulator (CFTR) modulators. METHODS: We conducted semistructured interviews with CF clinicians, adults with CF, and caregivers of children with CF. We reviewed audio recordings and coded responses to identify central themes. RESULTS: We interviewed 8 CF clinicians, 9 adults with CF, and 11 caregivers of children with CF. Themes centered on emotional responses to modulator availability, influences on decision-making, concerns about side effects, impact of modulators on planning for the future, the benefits of the multidisciplinary CF care team in supporting treatment decisions, and the unique needs of people with CF who are not eligible for modulators. Clinicians described changes in conversations about modulators since the approval of elexacaftor/tezacaftor/ivacaftor, specifically greater willingness to prescribe with less nuanced conversations with patients and/or caregivers regarding their use. CONCLUSION: Based on perspectives and experiences of CF clinicians, adults with CF, and caregivers of children with CF, we suggest clinicians approach conversations about CFTR modulators thoughtfully and thoroughly, utilizing the multidisciplinary model of CF care in exploring patient and caregiver emotions while filling in knowledge gaps, asking about treatment goals beyond potential clinical benefit, and having compassionate conversations with those who are ineligible for modulators.


Subject(s)
Aminophenols , Benzodioxoles , Caregivers , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/psychology , Cystic Fibrosis Transmembrane Conductance Regulator/drug effects , Adult , Female , Male , Child , Benzodioxoles/therapeutic use , Caregivers/psychology , Aminophenols/therapeutic use , Quinolones/therapeutic use , Decision Making , Indoles/therapeutic use , Middle Aged , Adolescent , Drug Combinations , Pyridines/therapeutic use , Young Adult , Interviews as Topic , Pyrazoles , Quinolines
19.
Molecules ; 29(4)2024 Feb 10.
Article in English | MEDLINE | ID: mdl-38398574

ABSTRACT

The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators-small molecules acting on the basic molecular defect in CF-have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA's) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.


Subject(s)
Aminopyridines , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Indoles , Pyrazoles , Pyridines , Pyrrolidines , Quinolones , Humans , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Quality of Life , Cystic Fibrosis/drug therapy , Cystic Fibrosis/genetics , Cystic Fibrosis/metabolism , Benzodioxoles/pharmacology , Benzodioxoles/therapeutic use , Aminophenols/pharmacology , Aminophenols/therapeutic use , Mutation , Chemistry Techniques, Synthetic
SELECTION OF CITATIONS
SEARCH DETAIL
...